Search
                    Pennsylvania Paid Clinical Trials
A listing of 3293  clinical trials  in Pennsylvania  actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
            1861 - 1872 of 3293
        
                Pennsylvania is currently home to 3293 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Philadelphia, Pittsburgh, Hershey and Allentown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
            
                                                Featured Trial
                
                Healthy Participants Needed (Colonoscopy + Cancer Screening)
            
        Recruiting
            
        Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
    
    
                            Conditions: 
                                    
        
            
                        Healthy
                    
                                    
                        Healthy Volunteers
                    
                                    
                        Healthy Subjects
                    
                                    
                        Healthy Volunteer
                    
                                    
                        Healthy Participants
                    
                                    Featured Offer
                
                Lose Weight with GLP-1 Medications
            
        Recruiting
            
        Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®. 
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
    GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
                            Conditions: 
                                    
        
            
                        Overweight
                    
                                    
                        Overweight and Obesity
                    
                                    
                        Obesity
                    
                                    
                        Weight Loss
                    
                                    
                        Morbid Obesity
                    
                                    Featured Trial
                
                Stroke Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Stroke
    
    
                            Conditions: 
                                    
        
            
                        Stroke
                    
                                    Featured Trial
                
                Chronic Kidney Disease (CKD) Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Chronic Kidney Disease (CKD)
    
    
                            Conditions: 
                                    
        
            
                        Chronic Kidney Disease (CKD)
                    
                                    Featured Trial
                
                Ischemic heart disease (IHD) Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Ischemic heart disease (IHD)
    
    
                            Conditions: 
                                    
        
            
                        Ischemic heart disease (IHD)
                    
                                    
                
                                    A Study to Find and Confirm the Dose and Assess Safety, Reactogenicity and Immune Response of a Vaccine Against Pandemic H5N1 Influenza Virus in Healthy Younger and Older Adults
                                
            
            
        Recruiting
                            
            
                The aim of this study is to evaluate the safety, reactogenicity and immunogenicity of the Flu Pandemic messenger RNA (mRNA) vaccine (including dose-finding and dose-confirmation) administered in healthy adults 18 to 85 years of age.             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 85 years
            Trial Updated:
                05/18/2025
            
            Locations: GSK Investigational Site, Philadelphia, Pennsylvania         
        
        
            Conditions: Influenza, Human
        
            
        
    
                
                                    Prostate Cancer Diagnosis by Multiparametric Ultrasound (Wholemount)
                                
            
            
        Recruiting
                            
            
                This phase III trial investigates if perflutren lipid microspheres with ultrasound can be used to diagnose prostate cancer non-invasively. Definity (perflutren lipid microspheres) is an ultrasound contrast agent that is typically used for ultrasound bubble studies that involve the heart. Definity appears on ultrasound images as tiny gas-filled microbubbles. These microbubbles are about the size of a red blood cell and do not stay in a patient's body for more than several minutes, where they are...  Read More             
        
        
    Gender:
                MALE
            Ages:
                18 years and above
            Trial Updated:
                05/17/2025
            
            Locations: Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania         
        
        
            Conditions: Prostate Carcinoma
        
            
        
    
                
                                    Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S03)
                                
            
            
        Recruiting
                            
            
                This clinical trial evaluates the use of self-collected vaginal samples for human papillomavirus (HPV) testing in patients referred for a colposcopy and/or cervical excisional procedures to improve cervical cancer prevention. HPV is a common virus which usually causes infections that last only a few months, but sometimes can last longer. HPV is known to cause a variety of cancers including cervical cancer. Even though there are ways to detect cervical cancer, many individuals are not diagnosed....  Read More             
        
        
    Gender:
                FEMALE
            Ages:
                25 years and above
            Trial Updated:
                05/16/2025
            
            Locations: University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania         
        
        
            Conditions: Cervical Carcinoma, Human Papillomavirus Infection
        
            
        
    
                
                                    A Registry for People With T-cell Lymphoma
                                
            
            
        Recruiting
                            
            
                The purpose of this registry study is to create a database-a collection of information-for better understanding T-cell lymphoma. Researchers will use the information from this database to learn more about how to improve outcomes for people with T-cell lymphoma.             
        
        
    Gender:
                ALL
            Ages:
                All
            Trial Updated:
                05/16/2025
            
            Locations: University of Pennsylvania (Data Collection Only), Philadelphia, Pennsylvania         
        
        
            Conditions: T-cell Lymphoma, NK-Cell Lymphoma, T-cell Prolymphocytic Leukemia, T-cell Large Granular Lymphocytic Leukemia, Chronic Lymphoproliferative Disorder of NK Cells, Aggressive NK-cell Leukemia, Systemic Epstein-Barr Virus Positive T-Cell Lymphoproliferative Disease of Childhood (Disorder), Systemic Epstein Barr Virus Positive T-Cell Lymphoproliferative Disease of Childhood, Chronic Active EBV Infection of T-and NK-Cell Type, Systemic Form, Hydroa Vacciniforme-Like Lymphoproliferative Disorder, Adult T-cell Leukemia/Lymphoma, Extranodal NK/T-cell Lymphoma, Nasal Type, Enteropathy-associated T-cell Lymphoma, Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma, Intestinal T-Cell Lymphoma, Not Otherwise Specified, Indolent T-Cell Lymphoproliferative Disorder of the Gastrointestinal Tract, Hepatosplenic T-cell Lymphoma, Subcutaneous Panniculitis-Like T-Cell Lymphoma, Mycosis Fungoides, Sezary Syndrome, Primary Cutaneous Anaplastic Large Cell Lymphoma, Primary Cutaneous T-cell Lymphoma, Primary Cutaneous CD8-Positive Aggressive Epidermotropic T-Cell Lymphoma, Primary Cutaneous Acral CD8-Positive T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma, Follicular T-Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Anaplastic Large Cell Lymphoma, ALK-Positive, Anaplastic Large Cell Lymphoma, ALK-negative, Breast Implant-Associated Anaplastic Large Cell Lymphoma
        
            
        
    
                
                                    Parkinson's Foundation PD GENEration Genetic Registry
                                
            
            
        Recruiting
                            
            
                Development of a central repository for PD-related genomic data for future research.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                05/16/2025
            
            Locations: University of Pennsylvania, Philadelphia, Pennsylvania         
        
        
            Conditions: Parkinson's Disease
        
            
        
    
                
                                    Systemic Hypothermia in Acute Cervical Spinal Cord Injury
                                
            
            
        Recruiting
                            
            
                This study is a prospective multi-center trial designed to determine the safety profile and efficacy of modest (33ºC) intravascular hypothermia following acute cervical (C1 to C8) Spinal Cord Injury (SCI).             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 70 years
            Trial Updated:
                05/16/2025
            
            Locations: Thomas Jefferson University, Philadelphia, Pennsylvania         
        
        
            Conditions: Spinal Cord Injury, Acute
        
            
        
    
                
                                    Phase 1b/2a Randomized Double-blind Study to Investigate Safety Tolerability PK PD Preliminary Efficacy of Oral Administration of SNIPR001 in Patients With Hematologic Malignancy Scheduled for Allogeneic Hematopoietic Stem-Cell Transplant Receiving FQ Prophylaxis & Harboring FQR Ecoli PreTransplant
                                
            
            
        Recruiting
                            
            
                This is a Phase 1b/2a study in allogenic hematopoetic stem cell transplant patients to investigate the safety, PK, PD and preliminary efficacy of multiple oral administrations of SNIPR001 when given concomitantly with SoC levofloxacin.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                05/15/2025
            
            Locations: UPMC, Pittsburgh, Pennsylvania         
        
        
            Conditions: E Coli Infections, Allogenic Transplant Patients
        
            
        
    
                
                                    Communication About Sexual Health in Gynecologic Cancer
                                
            
            
        Recruiting
                            
            
                The goal of this clinical trial is to learn if an educational video and workbook can help gynecologic cancer patients talk to their cancer providers about sexual health concerns.
The main questions it aims to answer are:
1. Do gynecologic cancer patients who take part in the educational program and get a resource booklet talk to their cancer clinicians more about sexual health concerns than patients who get a resource booklet alone?
2. Do gynecologic cancer patients who take part in the educat...  Read More             
        
        
    Gender:
                FEMALE
            Ages:
                18 years and above
            Trial Updated:
                05/15/2025
            
            Locations: Fox Chase Cancer Center, Philadelphia, Pennsylvania         
        
        
            Conditions: Gynecologic Cancers
        
            
        
    
                
                                    Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
                                
            
            
        Recruiting
                            
            
                This phase III trial compares the effect of olaparib for one year versus two years, with or without bevacizumab, for the treatment of BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer. Olaparib is a polyadenosine 5'-diphosphoribose polymerase (PARP) enzyme inhibitor and may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the format...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                05/15/2025
            
            Locations: Lehigh Valley Hospital-Cedar Crest, Allentown, Pennsylvania         
        
        
            Conditions: Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, FIGO Stage III Ovarian Cancer 2014, FIGO Stage IV Ovarian Cancer 2014, Ovarian Carcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Ovarian High Grade Endometrioid Adenocarcinoma
        
            
        
    
                
                                    Tailoring Therapy in Post-surgical Patients With Low-risk Endometrial Cancer
                                
            
            
        Recruiting
                            
            
                This phase II trial tests how well tailoring therapy in post-surgery works in patients with low-risk endometrial cancer. The usual approach for patients with low-risk endometrial cancer is treatment with surgery. In this study, tissue that is removed as part of the surgical procedure is analyzed in the pathology laboratory to help guide the doctor to decide whether or not additional treatment such as radiation and or chemotherapy should be recommended.             
        
        
    Gender:
                FEMALE
            Ages:
                18 years and above
            Trial Updated:
                05/15/2025
            
            Locations: Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania         
        
        
            Conditions: Stage I Uterine Corpus Endometrial Stromal Sarcoma AJCC V8, Stage II Uterine Corpus Endometrial Stromal Sarcoma AJCC V8, Stage III Uterine Corpus Endometrial Stromal Sarcoma AJCC V8
        
            
        
    
                
                                    Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic nHCM
                                
            
            
        Recruiting
                            
            
                This clinical trial will study the effects of aficamten (versus placebo) on the quality of life, exercise capacity, and clinical outcomes of patients with non-obstructive hypertrophic cardiomyopathy.             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 85 years
            Trial Updated:
                05/15/2025
            
            Locations: Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania         
        
        
            Conditions: Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy
        
            
        
    
                
                                    Open Label Trial of Oral Letermovir for CMV Prophylaxis in Thoracic Transplant Recipients
                                
            
            
        Recruiting
                            
            
                Open label study to determine tolerability and efficacy of letermovir for CMV prophylaxis in heart and lung transplant recipients. The study hypotheses are:
1. Letermovir prophylaxis will be associated with similar rates of CMV infection as valganciclovir among heart and lung transplant recipients
2. Letermovir will be better tolerated than valganciclovir for CMV prophylaxis in heart and lung transplant recipients, with a higher proportion of days of completed therapy with correct dosing during...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                05/15/2025
            
            Locations: Penn Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania         
        
        
            Conditions: Cytomegalovirus Infections, Transplant-Related Disorder
        
            
        
    